Repligen Option Alert: Dec 19 $150 Puts at the Bid: 1000 vs 761 OI; Earnings 2/20 Before Open 

Repligen Option Alert: Dec 19 $150 Puts at the Bid: 1000 @ $21.9 vs 761 OI; Earnings 2/20 Before Open Ref=$149.73

Repligen (NASDAQ:RGEN) 株価情報

Repligen

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

News

Movers

ACHC

CVLT

CWAN

DRVN

FTDR

HWKN

IDCC

LUMN

RGEN

SHAK

ZETA

過去１週間で最も成績を上げた７つの中型銘柄株、あなたのポートフォリオには入っていますか？

ルーメンテック　次世代光ファイバー供給に強み

Repligen Corp

RBC Capital analyst Conor McNamara maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Outperform and raises the price target from $203 to $205.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Repligen, Raises Price Target to $205

JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Overweight and raises the price target from $190 to $200.

JP Morgan Maintains Overweight on Repligen, Raises Price Target to $200

In the latest quarter, 4 analysts provided ratings for Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Repligen, revealing an average target of $173.75, a high estimate of $180.00, and a low estimate of $165.00. A decline of 10.9% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1740146428_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Repligen is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$170.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Announces</td>
<td>Hold</td>
<td>$165.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Repligen. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Repligen compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Repligen's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Repligen's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RGEN/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Repligen analyst ratings.</a>
<h2>Discovering Repligen: A Closer Look</h2>
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
<h3>Key Indicators: Repligen's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Repligen's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 9.69%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Repligen's net margin is impressive, surpassing industry averages. With a net margin of -0.42%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Repligen's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.03%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Repligen's ROA stands out, surpassing industry averages. With an impressive ROA of -0.02%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.33.
<h2>What Are Analyst Ratings?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Repligen In The Eyes Of 4 Experts

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Buy and maintains $180 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Repligen, Maintains $180 Price Target

Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Hold and raises the price target from $165 to $170.

Canaccord Genuity Maintains Hold on Repligen, Raises Price Target to $170

Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>)&nbsp;released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">but beating the consensus of 41 cents</a>.
The bioprocessing technology reported sales of $167.55 million, slightly up from $166.6 million a year ago, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43844804/repligen-reports-fourth-quarter-and-full-year-2024-financial-results" rel="noreferrer noopener">consensus of $167.67 million</a>.
Olivier Loeillot, President and Chief Executive Officer of Repligen, said, "During the fourth quarter, we were very encouraged by the continued momentum across our portfolio. Total revenue in the fourth quarter grew 13%, excluding COVID-19, overcoming two points of currency headwind. Total orders outpaced sales by 6%, driven by our Filtration and Analytics franchises&#8230;While we continue to monitor China and emerging biotech,&nbsp;the overall bioprocessing market is returning to growth. Our order momentum during the second half gives us confidence that we can achieve our 2025 guidance."
Guidance:&nbsp;Repligen expects 2025 sales of $685 million—$710 million, with organic growth of 9.5%—13.5% and non-COVID revenue growth of 10%—14% compared to the consensus of $694.86 million.
The company expects adjusted EPS of $1.67—$1.76 compared to the consensus of $1.73.
William Blair says Repligen's Q4 results and 2025 outlook confirm that the bioprocessing industry is recovering strongly, with growth expected to return to normal levels next year.
Repligen's guidance reflects strong quarterly momentum, signaling a market recovery.
Compared to peers like Danaher Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) and Avantor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NASDAQ">AVTR</a>), which project mid-to-high single-digit growth in bioprocessing, Repligen's outlook highlights its strong product portfolio and customer positioning that have driven consistent above-market growth.
Since Repligen focuses solely on bioprocessing and has minimal exposure to risks in NIH-funded research, academia, or China, analyst Matt Larew believes its guidance is more predictable than competitors with broader market and geographic exposure.
Price Action: RGEN stock is up 8.16% at $163.03 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43853635/hf-sinclair-reports-mixed-q4-results-with-weak-earning-weak-refining-margins-drive-93-drop-in-adjusted-ebitda" target="_blank" rel="noreferrer noopener">HF Sinclair Reports Mixed Q4 Results, Weak Refining Margins Drive 93% Drop In Adjusted EBITDA</a></li>
</ul>
Image via Repligen

Analyst Color

Earnings

Guidance

Health Care

Trading Ideas

General

AVTR

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

WIIM

Repligen shares are trading higher after the company reported better-than-expected Q4 financial results

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6">Reconciliation of Earnings Per Share (GAAP) Guidance to Adjusted Earnings Per Share (Non-GAAP) Guidance</td>
</tr>
<tr>
<td colspan="6">Year ending December 31, 2025</td>
</tr>
<tr>
<td colspan="3">Low End</td>
<td colspan="3">High End</td>
</tr>
<tr>
<td colspan="2">GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED</td>
<td>$</td>
<td>0.90</td>
<td>$</td>
<td>0.99</td>
</tr>
<tr>
<td colspan="2">ADJUSTMENTS TO GUIDANCE ON EARNINGS PER SHARE (GAAP) - DILUTED:</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Acquisition and integration costs</td>
<td>0.05</td>
<td>0.05</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Restructuring activities and other related charges</td>
<td>0.04</td>
<td>0.04</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Anticipated pre-tax amortization of acquisition-related intangible assets</td>
<td>0.62</td>
<td>0.62</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Non-cash interest expense</td>
<td>0.25</td>
<td>0.25</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Amortization of debt issuance costs</td>
<td>0.03</td>
<td>0.03</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Tax effect of non-GAAP charges</td>
<td>(0.21</td>
<td>)</td>
<td>(0.21</td>
<td>)</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Guidance rounding adjustment</td>
<td>—</td>
<td>—</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="2">GUIDANCE ON ADJUSTED EARNINGS PER SHARE (NON-GAAP) - DILUTED</td>
<td>$</td>
<td>1.67</td>
<td>$</td>
<td>1.76</td>
</tr>
</tbody>
</table>
</figure>

Repligen Sees FY2025 GAAP EPS $0.90-$0.99 Vs, $0.81 Estimate

Repligen Sees FY2025 Adj EPS $1.67-$1.76 vs $1.73 Estimate

Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.41 by 7.32 percent. This is a 8.33 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $167.55 million which missed the analyst consensus estimate of $167.67 million by 0.07 percent. This is a 0.56 percent increase over sales of $166.62 million the same period last year.

Earnings Beats

Earnings Misses

Repligen Q4 2024 Adj EPS $0.44 Beats $0.41 Estimate, Sales $167.55M Miss $167.67M Estimate

ACCO

AKAM

ALIT

ALRM

ARDX

ATHM

AXTI

BABA

BAND

BBDC

BBIO

BIGC

BILI

BIRK

BJRI

BKNG

BLDR

CARG

CCRD

CDRO

CELH

CENX

CERS

CGAU

COKE

COLD

CPRT

CRAI

CSTM

DAVA

DBRG

DGICA

DGICB

DINO

DVAX

EPAM

ESAB

EXPI

FIVN

FRPT

FYBR

GDYN

GKOS

GLOB

GLPI

GMED

GRAL

INDI

INDV

INOD

INSM

IRTC

ITGR

Earnings Scheduled For February 20, 2025

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Buy and lowers the price target from $240 to $180.

HC Wainwright & Co. Maintains Buy on Repligen, Lowers Price Target to $180

Repligen Announced The Commercial Launch Of Its CTech SoloVPE PLUS System For At-line Ultraviolet-visible Concentration Measurement In Complex Biological Production Workflows, From Process Development Scale Through cGMP Manufacturing

Canaccord Genuity analyst Kyle Mikson initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Hold rating and announces Price Target of $165.

Initiation

Canaccord Genuity Initiates Coverage On Repligen with Hold Rating, Announces Price Target of $165

Wolfe Research analyst Doug Schenkel initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Peer Perform rating.

Wolfe Research Initiates Coverage On Repligen with Peer Perform Rating

Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.
The bioprocessing technology reported sales of $154.87 million, up 10% year-over-year, beating the <a href="https://www.benzinga.com/pressreleases/24/11/g41897469/repligen-reports-third-quarter-2024-financial-results" target="_blank" rel="noreferrer noopener">consensus of $153.23 million</a>.
Olivier Loeillot, president and CEO of Repligen, said, "I'm pleased to report strong third-quarter results, made possible by the excellent execution by our team and improving market conditions. We are encouraged to see strengthening CDMO and equipment sales in the quarter, each delivering year-over-year and sequential growth.&#8221;
The company reported record quarterly revenue for new modalities, a 20% increase year over year. CDMO and equipment revenues grew ~20% and 6% year-over-year, respectively, adding to confidence in a broader market recovery.
Guidance: Repligen raises 2024 EPS guidance from 17 cents-24 cents to 25 cents-32 cents compared to a consensus estimate of 54 cents.
Repligen expects 2024 adjusted EPS of $1.50-$1.58 compared to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40044492/repligen-lowers-guidance-on-china-weakness-analyst-expects" rel="noreferrer noopener">prior guidance of $1.42-$1.49</a> and consensus of $1.43.
The company has narrowed sales guidance from $627 million-$642 million to $630 million-639 million versus the consensus of $628.98 million.
William Blair notes that after reaffirming expectations for low-double-digit organic growth in the second half of 2024 and receiving positive feedback from industry conferences, Repligen's third-quarter earnings show that the bioprocessing recovery is on track.
The company has narrowed its guidance, now expecting about 8% revenue growth in the fourth quarter compared to last year, aligning with William Blair's and market estimates and bioprocessing peers predicting mid- to high-single-digit growth for the year-end.
Additionally, Repligen highlighted strong sales in contract development and manufacturing (CDMO) and equipment, which is a positive sign.
The analyst believes Repligen is well-positioned for long-term growth thanks to its involvement in new modalities, strong R&amp;D capabilities, and clinical exposure.
William Blair maintained the <a href="https://www.benzinga.com/quote/RGEN/analyst-ratings" target="_blank" rel="noreferrer noopener">Outperform rating for Repligen</a>.
RGEN Price Action: Repligen stock is up 7.32% at $149.72 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41906923/treehouse-foods-stumbles-as-sales-dip-and-griddle-recall-hits-q3-earnings-ceo-bets-on-future-margins" target="_blank" rel="noreferrer noopener">TreeHouse Foods Stumbles As Sales Dip And Griddle Recall Hits Q3 Earnings; CEO Bets on Future Margins</a></li>
</ul>
Photo: Courtesy Repligen

Tech

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$42.6K</td>
<td>3.5K</td>
<td align="right">672</td>
</tr>
<tr>
<td>DOCS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$62.50</td>
<td>$50.2K</td>
<td>2</td>
<td align="right">446</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$30.00</td>
<td>$28.1K</td>
<td>7.0K</td>
<td align="right">252</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$51.9K</td>
<td>1.1K</td>
<td align="right">72</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$35.00</td>
<td>$34.0K</td>
<td>38</td>
<td align="right">71</td>
</tr>
<tr>
<td>JANX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$50.00</td>
<td>$36.6K</td>
<td>595</td>
<td align="right">61</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$27.0K</td>
<td>49</td>
<td align="right">59</td>
</tr>
<tr>
<td>IONS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$55.00</td>
<td>$25.0K</td>
<td>331</td>
<td align="right">50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$100.00</td>
<td>$41.7K</td>
<td>1.1K</td>
<td align="right">42</td>
</tr>
<tr>
<td>RGEN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$130.00</td>
<td>$33.0K</td>
<td>21</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 430 day(s) on January 16, 2026. Parties traded 49 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $42.6K, with a price of $870.0 per contract. There were 3515 open contracts at this strike prior to today, and today 672 contract(s) were bought and sold. 
• Regarding DOCS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), we observe a put option trade with bearish sentiment. It expires in 185 day(s) on May 16, 2025. Parties traded 54 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 2 open contracts at this strike prior to today, and today 446 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 402 day(s) on December 19, 2025. Parties traded 225 contract(s) at a $30.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $125.0 per contract. There were 7032 open contracts at this strike prior to today, and today 252 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option trade with bullish sentiment. It expires in 66 day(s) on January 17, 2025. Parties traded 30 contract(s) at a $315.00 strike. The total cost received by the writing party (or parties) was $51.9K, with a price of $1730.0 per contract. There were 1132 open contracts at this strike prior to today, and today 72 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be bullish, expiring in 276 day(s) on August 15, 2025. This event was a transfer of 50 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $680.0 per contract. There were 38 open contracts at this strike prior to today, and today 71 contract(s) were bought and sold. 
• For JANX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), we notice a put option sweep that happens to be bullish, expiring in 38 day(s) on December 20, 2024. This event was a transfer of 61 contract(s) at a $50.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $36.6K, with a price of $601.0 per contract. There were 595 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on December 20, 2024. This event was a transfer of 36 contract(s) at a $340.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $27.0K, with a price of $750.0 per contract. There were 49 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For IONS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>), we notice a call option trade that happens to be bullish, expiring in 794 day(s) on January 15, 2027. This event was a transfer of 50 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 331 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be neutral, expiring in 66 day(s) on January 17, 2025. This event was a transfer of 39 contract(s) at a $100.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $41.7K, with a price of $1070.0 per contract. There were 1154 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding RGEN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on November 15, 2024. Parties traded 20 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $1650.0 per contract. There were 21 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

DOCS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IONS

JANX

TGTX

10 Health Care Stocks Whale Activity In Today's Session

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3">CURRENT GUIDANCE (at November 12, 2024)</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>FY 2024</td>
<td>GAAP</td>
<td colspan="2">Adjusted (non-GAAP)</td>
</tr>
<tr>
<td>Total Reported Revenue</td>
<td>$630M - $639M</td>
<td colspan="2">$630M - $639M</td>
</tr>
<tr>
<td>Year-over-Year Change</td>
<td>0% - 1%</td>
<td colspan="2">0% - 1%</td>
</tr>
<tr>
<td>Base Revenue Growth</td>
<td>-</td>
<td colspan="2">(1%) - 0%</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>49.5% - 50.5%</td>
<td colspan="2">49.5% - 50.5%</td>
</tr>
<tr>
<td>Income from Operations</td>
<td>$12M - $17M</td>
<td colspan="2">$80M - $85M</td>
</tr>
<tr>
<td>Operating Margin</td>
<td>2% - 3%</td>
<td colspan="2">12.5% - 13.5%</td>
</tr>
<tr>
<td>Other Income (Expense)</td>
<td>$10M</td>
<td colspan="2">$27M</td>
</tr>
<tr>
<td>Adjusted EBITDA Margin</td>
<td>-</td>
<td colspan="2">17.5% - 18.5%</td>
</tr>
<tr>
<td>Tax Rate on Pre-Tax Income</td>
<td>33%</td>
<td colspan="2">20%</td>
</tr>
<tr>
<td>Net Income</td>
<td>$14M - $18M</td>
<td colspan="2">$85M - $89M</td>
</tr>
<tr>
<td>Earnings Per Share - Diluted</td>
<td>$0.25 - $0.32</td>
<td colspan="2">$1.50 - $1.58</td>
</tr>
</tbody>
</table>
</figure>

Repligen Raises FY24 Adj EPS Guidance from $1.42-$1.49 to $1.50-$1.58 vs $1.43 Est

Repligen Raises FY24 GAAP EPS Guidance from $0.17-$0.24 to $0.25-0.32 vs $0.54 Est; Narrows Sales Guidance from $627.00M-$642.00M to $630.00M-639.00M vs $628.98M Est

Repligen shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

Press Releases

Repligen to Report Third Quarter 2024 Financial Results

Repligen Corporation to Present at Upcoming Investor Conferences

Repligen Reports Third Quarter 2024 Financial Results

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

Repligen Announces Publication of the Company's 2023 Corporate Sustainability Report

Small Cap

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

Repligen Launches the CTech™ SoloVPE® PLUS System

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results

BLFS

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Repligen

Unusual Options Activity for

ニュース

パートナーシップ

ベンジンガ・グローバル